Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948998 | 0.85 | TSHR (0.39) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL1459645 | 0.83 | ACHE (0.48) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL3220920 | 0.83 | CYP1A2 (0.35) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL6941036 | 0.81 | GABRA1 (0.52) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL8420785 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2A6TSHRALDH1A1CA1 | |
| SCHEMBL16956053 | 0.79 | TSHR (0.35) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL16955373 | 0.79 | ALDH1A1 (0.36) | CYP1A2CYP2A6ACHETSHRALDH1A1 | |
| SCHEMBL16953897 | 0.78 | ALDH1A1 (0.34) | CYP1A2CYP2A6TSHRALDH1A1CA1 | |
| SCHEMBL31168897 | 0.76 | ALDH1A1 (0.55) | CYP1A2TSHRALDH1A1CA1CA2 | |
| SCHEMBL1713099 | 0.76 | ALDH1A1 (0.55) | CYP1A2TSHRALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401999-B | Process for preparing high sulfur content copolymers | 艾尼股份公司 | 2023-11-14 | — | — | CN | claimed |
| US-20220267487-A1 | PROCESS FOR HIGH SULFER CONTENT COPOLYMER PREPARATION | ENI S.P.A. (IT) | 2022-08-25 | — | — | US | claimed |
| EP-3997134-A1 | PROCESS FOR HIGH SULFUR CONTENT COPOLYMER PREPARATION | ENI S.p.A. (IT) | 2022-05-18 | — | — | EP | claimed |
| CN-114401999-A | Process for preparing high sulfur content copolymers | 艾尼股份公司 | 2022-04-26 | — | — | CN | claimed |
| WO-2021005511-A1 | PROCESS FOR HIGH SULFUR CONTENT COPOLYMER PREPARATION | ENI S.P.A. (IT) | 2021-01-14 | — | — | WO | claimed |
| US-20250066377-A1 | AMINO CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-114401999-B | Process for preparing high sulfur content copolymers | 艾尼股份公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023114539-A1 | AMINO CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-112358459-B | Preparation method of benzofuran compound | 心远(广州)药物研究有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220267487-A1 | PROCESS FOR HIGH SULFER CONTENT COPOLYMER PREPARATION | ENI S.P.A. (IT) | 2022-08-25 | — | — | US | disclosed |
| EP-3997134-A1 | PROCESS FOR HIGH SULFUR CONTENT COPOLYMER PREPARATION | ENI S.p.A. (IT) | 2022-05-18 | — | — | EP | disclosed |
| CN-114401999-A | Process for preparing high sulfur content copolymers | 艾尼股份公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-6458967-B1 | REACTING ACETYLENE COMPOUNDS TO FORM ENOL ETHER; REACTING WITH SULFUR OR SELENIUM OR TELLURIUM COMPOUND TO FORM DYE PRODUCT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-10-01 | — | — | US | disclosed |
| US-20020022723-A1 | Method for preparation of an intermediate dye product | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE STATE UNIVERSITY OF NEW YORK AT BUFFALO | 2002-02-21 | — | — | US | disclosed |
| WO-2002000642-A1 | METHOD FOR PREPARATION OF AN INTERMEDIATE DYE PRODUCT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | CYP1A2 1233/4885CYP2A6 1523/4885ACHE 666/4885 |
| US-20020022723-A1 | Method for preparation of an intermediate dye product | SRD5A1, SRD5A2, RER1 | CYP1A2 120/4885CYP2A6 1241/4885ACHE 1380/4885 |
| US-20250066377-A1 | AMINO CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | CYP1A2 1811/4885CYP2A6 3548/4885ACHE 4193/4885 |
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | CYP1A2 1025/4885CYP2A6 1352/4885ACHE 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.